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Protein-ligand interactions underlie a host of biological processes including cell signaling and 
antibody-antigen recognition, but a comprehensive understanding of the physiochemical properties 
dictating both high affinity and specificity of a protein for a particular ligand has been elusive.  The 
ability to computationally design a protein with high affinity and selectivity for a given ligand 
represents a rigorous test of the understanding of the principles governing protein-ligand interactions 
and could potentially be used to design ligand-binding proteins with defined specificities for use in 
biosensors, therapeutics, and diagnostics.  However, previous attempts at computational design of 
ligand-binding proteins have been largely unsuccessful as evidenced by discrepancies between 
computational models and structural and biophysical studies of designed proteins (Schrier et 
al., 2009).  Thus, current methods of designing ligand-binding proteins rely upon directed evolution 
of proteins with some measure of affinity for the target ligand and/or standard methods of raising 
antibodies against a target antigen.  However, these methods do not allow complete control over 
binding interactions. 
A new study from the laboratories of Drs. Barry Stoddard (Basic Sciences Division) and David Baker 
(University of Washington) as well as additional collaborators at UW and Rutgers University, 
published in Nature describes the first successful computational design and in vitro characterization 
of two ligand-binding proteins using a novel approach that may someday "open up a new strategy to 
create systems that combine the tumor targeting properties of antibodies with the therapeutic activity 
of traditional chemotherapy agents," says Dr. Stoddard. 
The authors set out to design proteins with high affinity and selectivity for the steroid digoxigenin 
(DIG), a derivative of the cardiac glycoside digoxin, which is used in the treatment of heart 
disease.  The authors’ computational approach took into account several characteristics of naturally 
occurring ligand-binding sites: (1) energetically favorable van der Waals interactions and hydrogen 
bonding; (2) shape complementarity to the ligand; and (3) structural organization of the binding site 
prior to ligand binding.  Using these criteria, the authors designed 17 DIG-binding proteins that were 
then experimentally characterized.  Designed proteins were expressed on the surface of yeast cells 
(yeast surface display) and tested for DIG binding using fluorescence-activated cell sorting (FACS) 
after incubation with DIG-biotin derivatives and a streptavidin-conjugated fluorophore.  Two of the 
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tested proteins, DIG5 and DIG10, bound DIG with affinities in the low-to-mid micromolar range, with 
DIG10 showing higher affinity towards DIG. 
To further enhance the affinity of DIG10 for DIG, the authors performed saturation mutagenesis, 
testing the effects of every possible amino acid substitution on this interaction.  This yielded the 
DIG10 variant DIG10.1, which displayed a 75-fold increase in affinity for DIG over DIG10.  The 
authors next generated a binding fitness map of 39 residues designed to interface with DIG by 
testing a library of variant proteins with 1-3 amino acid substitutions at each of these positions for 
DIG affinity.  DIG10.1 variants with increased affinity for DIG were subjected to high-throughput 
sequencing to identify the frequency of these mutations in FACS-sorted cells.  Further selection led 
to DIG10.3, which displayed picomolar affinity towards DIG.  Notably, the affinity of DIG10.3 for DIG 
was comparable to that of anti-digoxin antibodies. 
In addition to DIG, DIG10.3 was also able to bind the steroids digitoxigenin, progesterone, and b-
estradiol with affinities consistent with the loss of one, two, and three hydrogen bonds, respectively, 
between the molecule and binding pocket within the protein, indicating that these molecules bind the 
DIG10.3 binding pocket in the same orientation as DIG.  Strikingly, the steroid specificity of DIG10.3 
could be altered by the mutation hydrogen-bonding amino acid residues in its steroid binding 
pocket.  These results indicate that the high specificity of DIG10.3 for DIG is generated through 
designed hydrogen bonds. 
The researchers are now turning their computational approach to the design of proteins for cancer 
therapy.  Says Dr. Stoddard, "We are now working hard on studying the structure and mechanism of 
chimeric antigen receptors (protein molecules that are expressed on the surface of engineered T-
cells for immunotherapy) and hope to one day be able to use protein engineering to create new 
types of antitumor targeting receptors that act to direct reprogrammed T-cells and accompanying 
chemotherapeutic agents directly to individual tumor cells." 
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Image provided by Lindsey Doyle 
Ribbon diagram of the active site of the computationally 
designed protein DIG10.3 in complex with its ligand digoxigenin 
(DIG). DIG-interacting residues of DIG10.3 are colored yellow 
and DIG is colored pink. 
 
